Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

摘要: Cisatracurium besilate (besylate) is a nondepolarising neuromuscular blocking agent with an intermediate duration of action. It the R-cis, R'-cis isomer atracurium and approximately 3-fold more potent than mixture isomers that constitute parent drug. The ED95 for cisatracurium (dose required to produce 95% suppression twitch response nerve stimulation) in adults 0.05 mg/kg during N2O/O2 opioid anaesthesia. As besilate, primary route elimination by spontaneous degradation. not associated dose-related histamine release (at bolus doses < or = 8 x ED95) and, consistent this, has demonstrated cardiovascular stability both healthy patients (< those coronary artery disease 6 ED95). In clinical trials, been used successfully facilitate intubation 2 4 as muscle relaxant surgery intensive care. Compared vecuronium, was significantly faster recovery after continuous infusion Relative lower propensity cause but slightly longer onset time at equipotent doses. also offers predictable profile vecuronium prolonged use Thus, comparative data provide some indication potential intermediate-duration further comparisons other like agents are define precisely its relative merits.